Boston Scientific Corp. vs Abbvie Inc.
BSX vs ABBV — side-by-side comparison from reported financials. BSX leads 7, ABBV leads 5 of 12 comparable metrics.
Boston Scientific Corp.
BSX · Healthcare
$42.62+1.37%Solid
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
| Metric | BSX | ABBV |
|---|---|---|
| Price | $42.62 | $276.43 |
| Market cap | $61.8B | $488B |
| Revenue (TTM) | $21.0B | $64.4B |
| Revenue growth | +16.5% | +1.8% |
| Net margin | 17.5% | 9.8% |
| Free cash flow | $3.63B | $18.2B |
| Net cash (debt) | ($9.47B) | ($56.2B) |
| 1-year price return | -56.2% | +19.8% |
| P/E | 16.9 | 77.4 |
| P/E vs own history (cheap-side %) | 99% | 23% |
| Dividend yield | 0.00% | 2.45% |
| Return on equity | 15% | 96% |
| Altman Z-score | 2.58 | 2.33 |
| CV checks passed | 10 of 11 | 9 of 11 |
| Employees | 59,000 | 57,000 |
Full résumé-style profiles: BSX CV · ABBV CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.